Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Jun 07, 2024
Ose-279 100Mg, Ose-279 300Mg, Ose-279 500Mg
Lymphoma, Solid Advanced Tumor
Phase I/II
Recruiting
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
Jan 30, 2023
―
Covepit (Ose13e)
Coronavirus Disease (Covid-19)
Phase I
Unknown
To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults
May 07, 2021
―
Ose-127
Ulcerative Colitis
Phase II
Completed
Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis
Apr 13, 2021
―
Bi 765063, Bi 754091
Solid Tumor, Adult
Phase I
Completed
A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours
May 21, 2019
―
Ose-127
Healthy Subjects
Phase I
Completed
Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of OSE-127 in Healthy Subjects
May 13, 2019
―
Fr104
Rheumatoid Arthritis, Complication Of Transplant
Phase I
Completed
Safety, Tolerability, PK, PD, and Immunogenicity of Single and Multiple Ascending Intravenous Doses of FR104
May 20, 2016
―
Docetaxel, Pemetrexed, Ose2101
Non Small Cell Lung Cancer
Phase III
Terminated
OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure
Jan 08, 2016
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does OSE Immunotherapeutics SA (6OP) have in its pipeline
6OP is currently developing the following drugs: Docetaxel, Ose2101, Ngs Hlaa2 Assay, Ose-279 100Mg, Ose-279 300Mg, Ose-279 500Mg, Covepit (Ose13e). These drug candidates are in various stages of clinical development as the company works toward FDA approval.